R&D Partner Content 5th Gene Therapy for Ophthalmic Disorders Summit Ophthalmic drug developers are unlocking the full potential of gene therapy.
Partner Content Partner Content Exclusive interview with ForwardVue Pharma released for Opht... Exclusive interview with ForwardVue Pharma
Partner Content Partner Content Ophthalmic Drug Delivery Development - Trials and Tribulatio... Ophthalmic Drug Delivery Development Workshop
Partner Content Partner Content Novel Platforms in Ocular Drug Delivery workshop discussed a... Novel Platforms in Ocular Drug Delivery workshop
Partner Content Partner Content Aerie Pharmaceuticals interview released for Ophthalmic Drug... Ophthalmic Drugs
News Ambros' $125m for pain disorder drug, and other financings Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
